Susoctocog alfa
| Clinical data | |
|---|---|
| Trade names | Obizur |
| Other names | Antihemophilic factor (recombinant) |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Drug class | Antihemophilic factor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.[4][3][5]
Susoctocog alfa was approved for medical use in the United States in October 2014,[6][7] and for medical use in the European Union in November 2015.[4]
Factor VIII is one of the proteins needed for normal clotting of the blood.[4]
References
- ↑ "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Retrieved 6 March 2020.
- ↑ "Obizur 500 U powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 13 April 2017. Retrieved 3 September 2020.
- 1 2 "Obizur (antihemophilic factor- recombinant, porcine sequence kit". DailyMed. 2 January 2020. Retrieved 6 March 2020.
- 1 2 3 4 "Obizur EPAR". European Medicines Agency. 6 March 2020. Retrieved 6 March 2020.
- ↑ Burness CB, Scott LJ (May 2016). "Susoctocog Alfa: A Review in Acquired Haemophilia A". Drugs. 76 (7): 815–21. doi:10.1007/s40265-016-0576-1. PMID 27098420.
- ↑ "Obizur". U.S. Food and Drug Administration (FDA). 13 March 2018. Archived from the original on 23 April 2019. Retrieved 6 March 2020.
- ↑ "Obizur". U.S. Food and Drug Administration (FDA). 27 September 2019. STN: BL 125512. Retrieved 6 March 2020.
External links
- "Susoctocog alfa". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.